#3BBDeepDives
You're the CEO of your health. Don't let your health be limited by your healthcare.
The future of healthcare is participatory.
Follow the conversation
Every topic below links directly from our social posts — the deep dive behind the headline.
"60% of men and 56% of women will experience a heart attack, stroke, heart failure, or die of heart disease in their lifetime." — Framingham Heart Study (Lloyd-Jones et al., Circulation 2006)
A standard 10-minute clinic visit barely scratches the surface of your cardiovascular biology. Below is the clinical foundation of our framework — organized as 30 research topics. These topics form the core of our social media campaign. When we share a topic online, the link brings you directly to its clinical dashboard below, automatically expanded so you can verify the research. Expand any area to review the peer-reviewed studies, visualize the diagnostic pathways, and ask Corwin questions.
This content is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Heart disease can feel inevitable. It isn't. The idea that a heart attack strikes "out of nowhere" is one of the most disproven claims in modern cardiology: some of the most compelling evidence in cardiovascular medicine shows that the vast majority of heart attacks and coronary events are linked to a relatively small number of identifiable, modifiable risk factors — not fate, and not genes alone.[32] And this isn't based on one study, one population, or one country. Three landmark studies — two enormous Harvard cohorts of women and men, and the international INTERHEART study spanning 52 countries — arrive at the same message from completely different directions. This is the population statistic that gives 90 Nation its name.
In 2000, Harvard researchers analyzed 84,129 women in the Nurses' Health Study who were free of diagnosed cardiovascular disease, cancer, and diabetes at baseline. Over 14 years of follow-up they documented 1,128 major coronary events — and they scored every woman on five low-risk lifestyle factors: not smoking, a BMI below 25, at least 30 minutes of moderate-to-vigorous activity a day, a healthful diet, and moderate alcohol consumption. Women who met all five criteria had a relative risk of just 0.17 compared with women who met none — an approximately 83% lower risk of major coronary events.[30]
The same question was then examined in men through Harvard's Health Professionals Follow-up Study — an ongoing cohort begun in 1986 with more than 51,000 male health professionals, designed specifically to complement the Nurses' Health Study. Researchers followed 42,847 men who were free of cardiovascular disease, diabetes, and cancer at baseline, evaluated the same five lifestyle factors, and documented 2,183 coronary heart disease events over 16 years. The results were strikingly similar: men who met all five low-risk criteria had a relative risk of only 0.13 — an 87% lower risk of coronary heart disease — and an estimated 62% of coronary events could potentially have been prevented through better adherence to those five practices.[33]
The Harvard cohorts were powerful, but they largely involved U.S. health professionals. So what happens when you look across the world? The INTERHEART study, published in The Lancet in 2004, examined 15,152 people who had just experienced a first myocardial infarction and 14,820 controls across 52 countries — and identified nine potentially modifiable factors: abnormal blood lipids, smoking, hypertension, diabetes, abdominal obesity, psychosocial factors, low fruit and vegetable intake, physical inactivity, and alcohol.[29]
This is where the often-quoted "90% of heart attacks are preventable" statistic comes from — and the fine print matters. Technically, INTERHEART showed that approximately 90–94% of the population-attributable risk of a first heart attack was associated with these nine factors. That doesn't mean exactly 90% of individual heart attacks can be guaranteed to be prevented. It means that, at the population level, the overwhelming majority of heart-attack risk was statistically attributable to factors that can be identified and changed. That's an important distinction — and an incredibly powerful finding.
Different populations, different study designs, different geographic settings — and the conclusions point in the same direction. In women: ~83% lower individual risk of major coronary events. In men: ~87% lower individual risk of coronary heart disease. Across 52 countries: ~90–94% of population-attributable risk tied to modifiable factors. Most heart attacks are not random events. They emerge from the cumulative effects of smoking, metabolic dysfunction, blood pressure, abnormal lipids, visceral adiposity, physical inactivity, diet, and the other drivers above. Genetics matter. Age matters. Family history matters. But they are not the whole story — even a high inherited risk is not a sentence.
All of which means there is an enormous window for prevention. You don't have to wait until your arteries are severely narrowed. You don't have to wait until you have chest pain. You don't have to wait until conventional risk factors become dramatically abnormal — and you certainly don't have to wait for a first heart attack. The opportunity is to identify risk early, understand what is driving it, and address it before disease ever becomes an emergency. That's the difference between reactive cardiovascular care and proactive cardiovascular prevention.
This is where traditional and functional medicine meet. Conventional epidemiology proved that ~90% of population-level risk is attributable to nine countable risk factors. Functional medicine explains why — and gives you the earlier, measurable, actionable levers, often decades before symptoms appear. Standard care assesses a heart attack the way our sister topic The Full Picture describes: roughly 9 variables in a risk calculator. The functional lens evaluates 30+, because underneath each conventional risk factor sits a deeper root-cause driver you can actually measure and move.
None of this is anti-traditional. The science available to prevent heart disease has simply outpaced standard clinical practice. The nine INTERHEART factors are real and they matter — but they are the surface. Here is how the two views stack together — the conventional risk factor on top, the functional root cause you can measure beneath it:
The goal isn't perfection — it's prevention. Biology is probabilistic, and no program can promise to prevent an individual heart attack. But most of this risk lives in factors that are knowable early and changeable. Know your risk. Find the drivers — lipids and ApoB, insulin resistance, inflammation, blood pressure, and the lifestyle physiology beneath them. Address them early, years before they ever show up as a symptom — and give yourself the best possible chance of preventing the event in the first place. This is what supports your conversation with your physician, rather than replacing it. You are the CEO of your health.
For educational purposes only — not medical advice.
Corwin walks the whole argument in 65 seconds — the surface factors, the root causes beneath them, and what to do next.
From the deep dive
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study)
Case-control study of 15,152 first heart attacks and 14,820 controls in 52 countries. Nine potentially modifiable risk factors accounted for ~90% of the population-attributable risk of myocardial infarction in men and 94% in women — consistent across regions, ethnic groups, and sexes.
Primary prevention of coronary heart disease in women through diet and lifestyle
In 84,129 women followed 14 years (1,128 major coronary events), those meeting all five low-risk lifestyle criteria had a relative risk of 0.17 — an ~83% lower risk — with an estimated 82% of coronary events potentially preventable had all women been in the low-risk category.
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
Across ~55,000 participants, a favorable lifestyle was associated with a ~46% lower relative risk of coronary events even among those at highest genetic risk (standardized 10-year rate 10.7% → 5.1%). Genetic risk and lifestyle contribute independently.
Healthy lifestyle factors in the primary prevention of coronary heart disease among men
In 42,847 men followed 16 years (2,183 events), meeting all five low-risk criteria carried a relative risk of 0.13 — an 87% lower risk of coronary heart disease. An estimated 62% of events were potentially preventable — and 57% even among men already taking antihypertensive or lipid-lowering medication.
Low-Risk Diet and Lifestyle Habits in the Primary Prevention of Myocardial Infarction in Men
In a population-based cohort of Swedish men, adherence to five low-risk behaviors was associated with an ~86% lower rate of myocardial infarction versus men with none — reinforcing that most first MIs are attributable to modifiable factors.
Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 countries (PURE)
Across 21 high-, middle-, and low-income countries, modifiable risk factors accounted for roughly 70% of cardiovascular disease cases — replicating, on a global scale, that most CVD is attributable to identifiable, changeable drivers.
A living cross-section
Every one of them runs through the same artery wall. Here is what happens inside that wall, in five steps — and exactly what we measure at each one.
A healthy artery is lined with a slick, gel-like layer only a few cells thick. While it is intact, particles in the bloodstream glance off instead of sticking. It is the first thing lost — long before any plaque.
We measureA1C · Fasting insulin · Blood pressure · Uric acidStandard cholesterol tests estimate how much fat the particles are carrying. What actually matters is how many particles are hitting the wall — and every one of them carries exactly one ApoB. So we count them directly.
We measureApoB · Lp(a) · LDL particle numberWhere the shield gives way, particles lodge in the wall and oxidize. The body treats that as an injury and sends inflammatory cells in to clean it up — and that response, not the cholesterol itself, is what does the damage.
We measurehs-CRP · Lp-PLA2 · MPO · Oxidized LDLYears of that cycle build plaque inside the wall — a soft core under a thin cap. Blood tests infer it. A CCTA scan looks straight at it, and shows how much there is, where it sits, and how stable it looks.
We measureCCTA imaging with AI plaque analysisNone of this is fixed. The shield rebuilds, particle counts fall, inflammation settles, and plaque can stabilize. That is the whole point of measuring it — you can only steer what you can see.
We measureAll of the above — again, and again, over timeIllustrative model · not to anatomical scale. Educational information only — not medical advice, diagnosis, or a personal risk assessment.
This is the artery wall itself — the one your beats run through. Nothing here is on rails: set the markers where yours actually sit, walk the years forward, and watch what the wall does. Then run the scan and see which structures imaging can resolve and which it cannot.
How to drive it: pick a starting point, tap any marker to see where in the wall it acts, drag the years forward, then hit RUN CCTA.
A living cross-section
We empower you with deeper health intelligence. This is the wall those beats run through — and exactly what we measure in it.
Illustrative model · not to anatomical scale
Interactive model paused. Every reading below still responds to the controls.
Nine structures, lumen outward. Select one to find it above.
The cast in the image, by colour. Select one to see what it does.
Every marker feeds one of six mechanisms. These are what actually drive the wall.
Every marker acts somewhere specific. Select one to see where.
Tap any marker to see what it measures
What brings you here?
A quiet wall. Every marker where the evidence says it should be — not merely where a lab flags it.
Progression
20 yearsShield intact. Particles pass through and return. Nothing is retained.
Your markers set how fast. Most cardiovascular disease is silent for 10–30 years — this models that process, not a personal forecast.
Reference ranges
Same numbers. Different definition of “normal.” Flip it and nothing about your labs changes — only what counts as fine.
This is a stylized educational model of a biological process — not a scan, not a diagnosis, and not a depiction or prediction of any individual’s anatomy. Layer thicknesses are illustrative, not to anatomical scale, and marker values shown are illustrative composites. Imaging is performed and interpreted by licensed providers.
Chest pain, pressure, or shortness of breath right now? Call 911. In an acute heart attack, opening the artery is time-critical and life-saving. Nothing in this topic is medical advice, and nothing here is a reason to stop or change a treatment your doctor has prescribed.
The artery that gets opened is usually not the artery that causes the heart attack. That isn't a controversial claim — it has been tested in tens of thousands of patients. It just hasn't changed what most people are told.
A severe, calcified narrowing is what a stress test flags and an angiogram lights up — and by the time it's found, the body has often already routed around it with collateral vessels. The lesion that ruptures and causes the event is typically small, soft, inflamed, and somewhere else in the coronary tree — a plaque nobody was looking at, in an artery that would have passed the stress test.
So the question that actually predicts your future is not "where is the blockage?" but "how much unstable plaque is there, and why is it unstable?" Total plaque burden and composition — measurable with CCTA imaging and the labs that explain the injury — predict events better than the tightest narrowing.
An acute heart attack is a different problem entirely — opening the vessel fast saves heart muscle and saves lives. Angina that limits your life despite good medical therapy is a real, reasonable indication for relief of symptoms. And trials describe averages, not you: anatomy, symptoms, and history all matter, and your cardiologist's judgement comes first.
Optimal medical therapy with or without PCI for stable coronary disease (COURAGE)
2,287 patients with stable coronary disease randomized to PCI plus optimal medical therapy or medical therapy alone. Adding PCI did not reduce death or myocardial infarction over ~4.6 years of follow-up.
Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised sham-controlled trial
First sham-controlled PCI trial: 200 patients with severe single-vessel stenosis. PCI did not significantly improve exercise time versus a placebo procedure — quantifying how much of the perceived benefit in stable disease is not mechanical.
Initial invasive or conservative strategy for stable coronary disease (ISCHEMIA)
5,179 patients with moderate-to-severe ischemia on stress testing. A routine invasive strategy did not reduce ischemic cardiovascular events or death versus conservative management — symptom relief, yes; event prevention, no.
A prospective natural-history study of coronary atherosclerosis (PROSPECT)
697 patients imaged after an acute coronary event, then followed ~3.4 years. Roughly half of subsequent events arose from non-culprit lesions — plaques that were angiographically mild (mean ~32% stenosis) at baseline, i.e., blockages nobody would have stented.
Your doctor assesses your heart disease risk using a formula that checks 9 variables: age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, treatment for hypertension, diabetes status, and smoking status. That's it. This is the ASCVD risk calculator used by virtually every PCP and cardiologist in the country.
The science available to diagnose, treat and prevent heart disease has outpaced standard clinical practice. Don't let your health be limited by your healthcare. Heart disease is not just a cholesterol and plumbing problem — it is a complex multifactorial immunologic and metabolic disease process that starts decades before measurable disease and symptoms present.
From the functional medicine perspective, here is what actually causes or contributes to heart disease:
A 10-30 minute appointment twice a year cannot possibly assess all of this. 75% of all heart attacks are caused by poor metabolic health and inflammation which are not tested for by PCPs and cardiologists. The patient ends up needing to become their own advocate — or they simply don't get the full picture at all. You are the CEO of your health.
Lipid levels in patients hospitalized with coronary artery disease
Analysis of 136,905 hospitalizations. ~50% of heart attack patients had LDL <100 mg/dL ("normal"). Only 1.4% had "ideal" lipid profiles.
Novel Prediction Equations for Absolute Risk Assessment of Total CVD (PREVENT)
AHA's updated race-free risk equations. Adds eGFR, BMI, optional HbA1c. Replaces the old Pooled Cohort Equations.
Comparison of Novel Risk Markers for Improvement in CV Risk Assessment
CAC score outperformed other novel markers for risk reclassification in intermediate-risk individuals.
Prevalence of Optimal Metabolic Health in American Adults
Only 12.2% of American adults are metabolically healthy. 88% have at least one marker of metabolic dysfunction.
Heart disease is not just a cholesterol and plumbing problem — it is a complex multifactorial immunologic and metabolic disease process. The conventional model imagines cholesterol clogging arteries the way grease clogs a pipe. The reality is fundamentally different: atheroma forms from inside the artery wall, not from the surface.
Understanding the four-step cascade below changes how you think about prevention — because each step is addressable before it leads to plaque. Endothelial dysfunction and glycocalyx damage are the earliest findings in this process, occurring years or decades before any measurable blockage.
Your body is remarkably adaptive: 100% of the time an artery reaches 70% occlusion, the body builds collateral arteries — natural bypasses to maintain blood flow. This is why many heart attacks occur in arteries with less than 50% blockage. It's not the size of the plaque — it's the stability. Inflamed, vulnerable plaques rupture and trigger the clotting cascade that causes heart attacks.
Atherosclerosis — An Inflammatory Disease
Landmark paper establishing that atherosclerosis is fundamentally an inflammatory disease, not simply a lipid-storage disease. Endothelial dysfunction is the initiating event.
The Etiopathogenesis of Coronary Heart Disease: A Heretical Theory Based on Morphology
Autopsy analysis revealed that plaque is composed of ~87% clotting tissue (fibrin, platelets), challenging the cholesterol-centric model of atherosclerosis.
Collateral Circulation of the Heart
Demonstrated that coronary collateral arteries develop reliably when stenosis reaches ~70%, functioning as natural bypass vessels that maintain myocardial perfusion.
Vulnerable Atherosclerotic Plaque: Mechanisms of Rupture
Most acute coronary events arise from plaques with <50% stenosis that rupture. Plaque vulnerability — not stenosis severity — drives events.
Insulin resistance and high blood sugar create systemic stress, driving inflammation and altering lipid profiles.
Inflammation damages the delicate lining of the arteries (endothelium), making them "sticky" and vulnerable.
Atherogenic particles (ApoB) breach the damaged endothelium and become trapped in the arterial wall.
The immune system responds to the trapped lipids, leading to chronic inflammation and the formation of atherosclerotic plaque.
Insulin resistance is the central driver of cardiovascular risk — yet your standard physical almost certainly doesn't test for it. Two-thirds of people who have a heart attack have prediabetes or diabetes. According to the American Association of Clinical Endocrinologists, one-third of Americans are insulin resistant. It directly promotes hypertension, impairs nitric oxide production (which protects your arteries), drives systemic inflammation, and creates atherogenic dyslipidemia (small, dense LDL particles that penetrate artery walls more easily).[10, 11]
High insulin levels directly increase blood pressure through multiple mechanisms: insulin tells the kidneys to retain sodium, stimulates the sympathetic nervous system, and promotes arterial stiffness. 70% of people with hypertension have underlying insulin resistance — yet blood pressure is typically treated with medications alone, without ever investigating the metabolic root cause.
The conditions that stem from insulin resistance — prediabetes, metabolic syndrome, fatty liver disease, PCOS — are often treated as separate issues. In functional cardiology, they're understood as manifestations of the same root metabolic dysfunction.
Role of Insulin Resistance in Human Disease (Banting Lecture 1988)
Landmark lecture establishing insulin resistance as the central defect linking hyperinsulinemia, glucose intolerance, hypertension, and dyslipidemia — collectively termed "Syndrome X" (now metabolic syndrome).
Insulin Resistance and Cardiovascular Events: The Framingham Offspring Study
Demonstrated that addressing insulin resistance could prevent 42% of myocardial infarctions. Insulin resistance was an independent predictor of cardiovascular events even after adjusting for traditional risk factors.
Detection of Diabetes Mellitus In Situ (Occult Diabetes)
Analyzed over 14,000 glucose tolerance tests with concurrent insulin measurements. Showed that hyperinsulinemia precedes hyperglycemia by years to decades, and that fasting glucose alone misses the majority of metabolically dysfunctional patients.
Insulin Resistance, Hyperinsulinemia, and Coronary Artery Disease
Established the mechanistic links between insulin resistance, sodium retention, sympathetic nervous system activation, and hypertension — explaining why 70% of hypertensive patients are insulin resistant.
Scientists discovered in the 1990s that chronic inflammation — not dietary fat — is what actually damages your arteries. Dr. Paul Ridker at Harvard demonstrated a critical insight: if you have high LDL but no inflammation, there is no impact on heart disease risk. This fundamentally changes how you should think about prevention. The hidden variable is hs-CRP — a marker that most standard physicals never run.[6, 8]
The data is striking even among patients already on aggressive statin therapy. In the FOURIER trial, cardiovascular event rates climbed 12% to 18% as inflammation markers rose — even with LDL already lowered by statins. The SPIRE trial went further: patients with extremely low LDL but elevated inflammation had 62% more cardiovascular risk than those with low inflammation.
Chronic low-grade inflammation can be driven by insulin resistance, gut dysbiosis, dental infections, autoimmune conditions, environmental toxins, poor sleep, and chronic stress. It's not one thing — it's everything converging on your arterial walls.
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS)
Landmark trial proving that targeting inflammation (IL-1β) with canakinumab reduced cardiovascular events independent of lipid lowering — establishing inflammation as a causal, independent pathway in atherosclerosis.
Inflammatory Residual Risk in Statin-Treated Patients (FOURIER)
Among patients on evolocumab with very low LDL-C, cardiovascular event rates climbed 12-18% as inflammation (hs-CRP) rose. Residual inflammatory risk persists despite aggressive lipid lowering.
Rosuvastatin to Prevent Vascular Events (JUPITER)
Showed that statin therapy reduced events in patients with elevated hs-CRP but normal LDL-C — demonstrating that inflammation identification expands the population that benefits from intervention.
Inflammation and Cholesterol as Predictors of Events Among Patients Receiving Statin Therapy (SPIRE)
Patients with extremely low LDL but elevated inflammation (hs-CRP ≥2 mg/L) had 62% more cardiovascular risk than those with low inflammation — proving inflammation is the dominant residual risk driver.
The glycocalyx is the endothelium's first line of defense. Lining the interior of every blood vessel in your body is this microscopically thin, gel-like layer — only about 0.5 microns thick. Despite its size, it provides critical anti-inflammatory, antioxidant, and thromboresistant properties, regulating blood flow, preventing clot formation, and blocking lipoproteins from penetrating the arterial wall.[7, 24]
Beneath the glycocalyx, the endothelium produces nitric oxide (NO) — a molecule that dilates arteries, prevents platelet aggregation, and reduces inflammation. When the glycocalyx is degraded, nitric oxide production drops and the endothelium shifts from a protective to a pro-inflammatory, pro-thrombotic state. This is where atherosclerosis begins — before any plaque forms.
The glycocalyx is damaged by: hypertension, oxidized cholesterol, high blood sugar, smoking, environmental toxins, plastics, chronic infections, and heavy metals. Once damaged, the endothelium becomes "sticky" — allowing ApoB-containing lipoproteins to breach the arterial wall and initiating the cascade of plaque formation. Protecting your glycocalyx is protecting the foundation of vascular health.
The Endothelial Glycocalyx: Composition, Functions, and Visualization
Comprehensive review establishing the glycocalyx as a critical regulator of vascular homeostasis — providing mechanotransduction, anti-coagulant properties, and a barrier to lipoprotein penetration.
Degradation of the Endothelial Glycocalyx in Clinical Settings
Documented glycocalyx degradation by hyperglycemia, oxidized LDL, inflammatory cytokines, and ischemia-reperfusion injury. Loss of glycocalyx increases vascular permeability and promotes leukocyte adhesion.
The Endothelial Glycocalyx in Syndromes of Accelerated Atherosclerosis
Showed that patients with diabetes and metabolic syndrome have significantly reduced glycocalyx volume, correlating with increased vascular vulnerability and accelerated atherosclerosis.
Nitric Oxide and the Endothelium: History and Impact on Cardiovascular Disease
Nobel Prize-winning research establishing nitric oxide as the critical endothelium-derived relaxing factor, responsible for vasodilation, anti-thrombotic activity, and anti-inflammatory signaling in the vascular wall.
That LDL number your doctor checks? It measures the cholesterol mass inside your LDL particles. But the real risk comes from the number of particles (ApoB) trying to penetrate your artery walls — and most doctors don't test for it. A landmark analysis of 233,455 subjects confirmed ApoB as the most potent lipid predictor of cardiovascular risk, superior to LDL-C.[12, 25]
Think of it like traffic. LDL-C measures the total number of passengers (cholesterol). ApoB counts the number of cars (particles). More cars on the road means more chances for a crash into your artery wall — regardless of how many passengers each car is carrying.
LDL was never the enemy. LDL is a carrier — a delivery truck transporting cholesterol, phospholipids, antioxidants, CoQ10, and fat-soluble vitamins to every cell in your body. The problem isn't the LDL particle itself — it's an injured endothelium that allows particles to infiltrate and become trapped in the artery wall, triggering the immune cascade that builds plaque.
ApoB vs LDL-C in Estimating Cardiovascular Risk: A Large-Scale Analysis
Meta-analysis of 233,455 subjects confirmed ApoB as the most potent lipid marker of cardiovascular risk. When ApoB and LDL-C are discordant, risk tracks with ApoB — not LDL-C.
Discordance Between ApoB and LDL-C in Clinical Practice
Found 20-30% discordance rates between LDL-C and ApoB. In metabolic syndrome, LDL-C underestimated cardiovascular risk by over 40% compared to ApoB particle count.
Apolipoprotein B and Cardiovascular Disease: A Narrative Review
Comprehensive review establishing that ApoB is the best single measure of atherogenic lipoproteins, encompassing all particles capable of initiating and driving atherosclerosis.
Response to Retention of Lipoproteins in the Artery Wall
Established the "response-to-retention" hypothesis: atherosclerosis begins when ApoB-containing lipoproteins are retained in the arterial intima, not simply when circulating levels are elevated.
Comparing the predictive power (Relative Risk Ratio) of conventional vs. advanced cardiovascular markers.[25]
Lipoprotein(a) — or Lp(a) — is a genetically determined lipoprotein that you can't change with diet or exercise. It affects approximately 1 in 5 people, yet fewer than 0.5% have ever been tested. It's one of the most important independent risk factors for cardiovascular disease that most doctors never check because standard lipid panels don't include it.[13]
Unlike LDL-C, elevated Lp(a) doesn't respond to statins, diet, or exercise. It carries both cholesterol and a pro-thrombotic protein called apolipoprotein(a), making it doubly dangerous — promoting both plaque buildup and blood clot formation. Lp(a) is essentially an LDL particle with an extra sticky protein attached that makes it more inflammatory and more likely to cause clots.
The therapeutic landscape is changing rapidly. New RNA-based drugs are showing remarkable efficacy in clinical trials:
If your Lp(a) is high, discussing this with your doctor can help inform your overall risk assessment — including more aggressive management of other modifiable risk factors and potentially enrolling in clinical trials for these emerging therapies.
Lipoprotein(a) as a risk factor for cardiovascular disease
Established Lp(a) as a causal, independent risk factor for CVD and aortic stenosis. Recommended screening in high-risk populations.
Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction (OCEAN(a))
Olpasiran reduced Lp(a) by more than 95% in a dose-dependent manner with an acceptable safety profile.
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)
Lepodisiran produced dose-dependent reductions in Lp(a) up to ~94%, with effects lasting up to 48 weeks after a single dose.
2026 ACC/AHA Cholesterol Management Guidelines
For the first time, recommends universal Lp(a) screening for all adults, recognizing it as a critical independent risk factor.
Native LDL particles are relatively benign. It's when they become oxidized — through exposure to free radicals, high blood sugar, and inflammatory conditions — that they trigger the immune cascade that builds plaque. The pathway is clear: LDL enters the artery wall → becomes oxidized → scavenger receptors on macrophages engulf it → macrophages become foam cells → foam cells accumulate into atherosclerotic plaque.[9]
This is why two people with the same LDL-C level can have wildly different cardiovascular risk. One may have large, buoyant LDL particles that resist oxidation. The other may have small, dense particles that oxidize easily and drive plaque formation.
Sugar is a major driver of oxidation. Excess blood glucose damages the endothelium and accelerates LDL oxidation. Glycation — the process where excess sugar chemically bonds to proteins and lipids — creates Advanced Glycation End-products (AGEs). AGEs promote inflammation, stiffen arteries, and further damage the vascular lining. This is one reason why metabolic syndrome and diabetes are such powerful cardiovascular risk factors.
Oxidized LDL is one of the most direct biomarkers of active plaque formation. It measures whether your cholesterol is actually doing damage — not just whether it exists. If your doctor only checks total LDL-C, you're seeing less than half the picture.
Oxidized LDL and its clinical implication
Comprehensive review establishing oxidized LDL as a key initiator of atherosclerosis via macrophage scavenger receptor uptake and foam cell formation.
Small dense low-density lipoprotein as biomarker for atherosclerotic diseases
Small dense LDL particles are 3-7× more atherogenic due to increased oxidative susceptibility, greater arterial wall penetration, and prolonged plasma residence time.
Advanced glycation end products and their receptor (RAGE) in cardiovascular disease
AGEs formed through glycation promote endothelial dysfunction, arterial stiffness, and accelerated atherosclerosis through RAGE-mediated inflammatory signaling.
Oxidized phospholipids, Lp(a), and atherosclerosis
Demonstrated that oxidized phospholipids on LDL and Lp(a) are key mediators of inflammatory atherogenesis and potent biomarkers of cardiovascular risk.
70% of your immune system resides in your gut. A compromised gut barrier allows bacterial endotoxins (lipopolysaccharides) to leak into the bloodstream, triggering systemic inflammation and directly promoting atherosclerosis. This process — gut-derived low-grade endotoxemia — is now recognized as a significant contributor to cardiovascular disease.[16]
Gut dysbiosis can drive chronic inflammation that standard cardiovascular testing never traces back to its source. There are two major mechanisms connecting the gut to heart disease:
Conditions like IBS, Crohn's disease, and ulcerative colitis aren't just gastrointestinal issues — they're cardiovascular risk factors. The microbiome's influence extends to lipid metabolism, insulin sensitivity, and inflammatory signaling. If your inflammation markers are elevated but no one has looked at your gut or dental health, you may be missing the root cause.
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Landmark discovery of the TMAO pathway: gut bacteria metabolize dietary phosphatidylcholine to produce TMAO, which directly promotes atherosclerosis.
Intestinal microbiota metabolism of L-carnitine promotes atherosclerosis
Demonstrated that gut microbiota convert L-carnitine from red meat to TMAO, providing mechanistic links between red meat consumption and cardiovascular risk.
Metabolic endotoxemia initiates obesity and insulin resistance
First to demonstrate that gut-derived bacterial endotoxins (LPS) entering the bloodstream trigger systemic inflammation, insulin resistance, and metabolic dysfunction.
Periodontal disease and atherosclerotic vascular disease (AHA Scientific Statement)
AHA confirmed an association between periodontal disease and atherosclerotic cardiovascular disease, with oral bacteria identified in atherosclerotic plaques.
In 2024, the New England Journal of Medicine published a landmark finding: microplastics and nanoplastics were identified inside human arterial plaques — and their presence was associated with a 4.5-fold increase in cardiovascular events including heart attack, stroke, and death. Of the plaques analyzed, 58.4% contained polyethylene.[15]
The American Heart Association has formally recognized contaminant metals — lead, cadmium, and arsenic — as cardiovascular risk factors.[14] Air pollution, mold exposure, occupational chemicals, and heavy metals all contribute to vascular damage through oxidative stress, inflammation, and direct endothelial injury.
There is hope for intervention. The TACT trial (Trial to Assess Chelation Therapy) demonstrated a 39% reduction in cardiovascular events in diabetic patients treated with chelation therapy — suggesting that removing accumulated heavy metals can meaningfully reduce cardiovascular risk. Your environment is part of your cardiovascular risk profile, and it's more addressable than most people realize.
Microplastics and Nanoplastics in Atheromas and Cardiovascular Events
58.4% of arterial plaques contained polyethylene; patients with microplastics in plaques had 4.53× higher risk of CV events over 34 months.
Contaminant Metals as Cardiovascular Risk Factors (AHA Scientific Statement)
AHA formally recognized lead, cadmium, and arsenic as cardiovascular risk factors, contributing to atherosclerosis via oxidative stress and endothelial dysfunction.
TACT: Effect of Disodium EDTA Chelation on Cardiovascular Events
Chelation therapy produced a 39% reduction in cardiovascular events among diabetic patients, suggesting heavy metal removal can reduce CV risk.
PFAS Exposure and Cardiovascular Disease Risk
PFAS ("forever chemicals") detectable in 97%+ of Americans are associated with dyslipidemia, endothelial dysfunction, and increased cardiovascular risk.
BPA Exposure and Atherosclerosis in Animal Models
BPA exposure resulted in a 104% increase in atherosclerotic lesion area in mice, operating through pro-inflammatory and pro-atherogenic pathways.
Chronic psychological stress activates the hypothalamic-pituitary-adrenal axis, elevating cortisol, disrupting sleep architecture, promoting insulin resistance, and maintaining a state of low-grade systemic inflammation. The JAMA State of the Art Review on psychological stress and cardiovascular disease was unequivocal: chronic stress increases heart attack risk by almost 2-fold — equivalent to having both hypertension and diabetes.[17]
Stress doesn't just make you feel bad. It physically remodels your cardiovascular system: thickening arterial walls, promoting plaque instability, and increasing platelet aggregation. Catecholamine surges from chronic stress trigger a hypercoagulable state — your blood literally becomes more likely to clot during periods of emotional distress.
The evidence for stress intervention is compelling. The Mount Abu trial found that raja yoga meditation for 40 minutes per day was the single biggest factor in atherosclerosis reversal — outperforming dietary changes and exercise alone. Emotional health — relationships, community, purpose, happiness — isn't optional. Managing stress isn't self-care — it's cardiovascular medicine.
Psychological Stress and Cardiovascular Disease (JAMA State of the Art Review)
Comprehensive review establishing chronic psychological stress as a causal contributor to CVD, with risk equivalent to hypertension and diabetes combined.
Social isolation and loneliness as risk factors for CVD (AHA Scientific Statement)
AHA formally recognized loneliness and social isolation as cardiovascular risk factors, with mortality risk equivalent to smoking 20 cigarettes per day in those over 50.
Regression of coronary atherosclerosis through healthy lifestyle (Mount Abu Heart Study)
Raja yoga meditation (40 min/day) combined with lifestyle changes produced significant coronary atherosclerosis regression, with meditation as the single largest contributing factor.
Triggering of Acute Myocardial Infarction by Heavy Physical Exertion and Anger
Acute emotional stress and anger can trigger MI through catecholamine surges that promote platelet aggregation and coronary vasoconstriction.
Sleep isn't rest — it's repair. During deep sleep, your body regulates blood pressure, repairs endothelial damage, clears metabolic waste, and rebalances hormones. Chronic sleep deprivation — even losing just 1-2 hours per night — dramatically accelerates cardiovascular disease progression.
Obstructive sleep apnea (OSA) creates repeated episodes of oxygen deprivation throughout the night, triggering:
Each apnea event triggers a fight-or-flight response — spiking blood pressure, heart rate, and cortisol hundreds of times per night.
Intermittent hypoxia generates reactive oxygen species that damage the endothelium and accelerate plaque formation.
Disrupted circadian rhythm impairs glucose metabolism, increases insulin resistance, and elevates inflammatory markers.
Heart Rate Variability (HRV) — one of the most important wearable-tracked recovery metrics — drops significantly with poor sleep quality. Low HRV is associated with a 32-45% increased risk of first cardiovascular event. Sleep is when your autonomic nervous system resets and repairs.
Short Sleep Duration and Incident Coronary Artery Calcification
Adults sleeping fewer than 6 hours had significantly higher coronary artery calcium scores and accelerated subclinical atherosclerosis compared to those sleeping 7-8 hours.
Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement from the AHA
OSA is independently associated with hypertension, coronary artery disease, heart failure, arrhythmias, and stroke. Treatment with CPAP reduces cardiovascular events in severe OSA.
Sleep Duration and Cardiovascular Disease Risk: Epidemiologic and Experimental Evidence
Both short (<6 hrs) and long (>9 hrs) sleep duration are associated with increased cardiovascular morbidity and mortality in a U-shaped relationship.
Heart rate variability as a predictor of cardiovascular events: the ARIC study
Low HRV — strongly influenced by sleep quality — was associated with 32-45% increased risk of a first cardiovascular event, independent of traditional risk factors.
The conversation about nutrition in heart health usually stops at "eat less saturated fat." But that misses the bigger picture entirely. Cardiovascular health depends not just on what you eat, but on what you absorb, what you're deficient in, and what's being depleted by medications, stress, and environmental factors.
Key nutritional factors the CMO identifies as cardiovascular contributors:
Magnesium, vitamin D, omega-3 fatty acids, CoQ10, B vitamins, and vitamin K2 all play direct roles in cardiovascular function. Standard labs rarely test for them.
Statins deplete CoQ10. PPIs deplete magnesium and B12. Diuretics deplete potassium and magnesium. Metformin depletes B12. These are iatrogenic nutritional gaps.
Gut health, stomach acid levels, and microbiome composition directly impact nutrient absorption. You can eat perfectly and still be deficient if your gut isn't healthy.
Water quality, caffeine intake, and alcohol use are also part of the full nutritional picture. High caffeine intake can deplete magnesium and raise cortisol. Alcohol — even moderate consumption — increases homocysteine and depletes B vitamins. These factors rarely come up in a 10-minute cardiology appointment.
Subclinical magnesium deficiency: a principal driver of cardiovascular disease
Subclinical magnesium deficiency is widespread and independently associated with hypertension, coronary artery disease, arrhythmias, and sudden cardiac death.
Coenzyme Q10 supplementation and statin-related myalgia
Statins inhibit the mevalonate pathway, reducing CoQ10 synthesis by up to 40%. CoQ10 supplementation significantly reduced statin-associated muscle symptoms in meta-analysis.
Omega-3 Index as a Risk Factor for Cardiovascular Disease
An Omega-3 Index below 4% was associated with the highest risk of sudden cardiac death, while an index above 8% was cardioprotective.
Vitamin D deficiency and risk of cardiovascular disease
Vitamin D deficiency (<15 ng/mL) was associated with a 2× increased risk of cardiovascular events, even after adjusting for traditional risk factors.
Hormones are one of the most overlooked drivers of cardiovascular disease. Estrogen is profoundly cardioprotective — it maintains endothelial function, promotes favorable lipid profiles, reduces arterial stiffness, and has anti-inflammatory properties. When estrogen levels decline during menopause, women lose this protection rapidly.
The CMO notes that hormonal health — including menopause, andropause, and conditions like PCOS (now called Polyendocrine Metabolic Ovarian Syndrome/PMOS) — directly impacts cardiovascular risk through multiple mechanisms:
Loss of estrogen causes endothelial dysfunction, increased LDL oxidation, arterial stiffness, and central adiposity. CVD risk doubles within 10 years of menopause.
Declining testosterone in men is associated with increased visceral fat, insulin resistance, metabolic syndrome, and inflammatory markers — all cardiovascular accelerants.
Affects 1 in 10 women. Drives insulin resistance, chronic inflammation, dyslipidemia, and endothelial dysfunction — dramatically elevating lifetime CVD risk from a young age.
Thyroid disease is another hormonal condition with profound cardiovascular impact. Both hypothyroidism (which raises LDL and accelerates atherosclerosis) and hyperthyroidism (which causes arrhythmias and heart failure) are common and often undertreated.
Menopause and Cardiovascular Disease: An Evidence-Based Review
AHA scientific statement confirming menopause as an independent cardiovascular risk factor. Estrogen loss accelerates atherogenesis, arterial stiffness, and adverse lipid changes.
Low Testosterone and Cardiovascular Risk in Men
Low testosterone in men was associated with increased all-cause and cardiovascular mortality, independent of age, adiposity, and lifestyle factors.
Cardiovascular Disease Risk in Women with PCOS
Women with PCOS have significantly elevated cardiovascular risk factors from a young age — including insulin resistance, dyslipidemia, and chronic low-grade inflammation.
Thyroid Function and Cardiovascular Disease
Both overt and subclinical hypothyroidism are associated with increased cardiovascular morbidity — elevated LDL, diastolic hypertension, and accelerated atherosclerosis.
Greater than 50% of people who have a heart attack have normal cholesterol levels. For 25% of people, the first sign of heart disease is sudden death. A 2025 JACC study found that 45-61% of first MI patients under 65 wouldn't even qualify for a statin under current guidelines. Per preventative cardiologist Dr. Robert Hurst, 75% of heart attacks occur in people deemed low risk by conventional risk stratification calculators.
75% of myocardial infarctions come from unstable plaque rupture — plaques that narrow arteries by only 20-40%, without any previous angina or warning symptoms. Stress tests only detect blockages above 70%. They miss exactly the plaques that kill you. Calcium scores miss soft, non-calcified plaque entirely. These standard tests create a dangerous false sense of security.
Try the Artery Plaque Simulator in the Explore tab to see how different diagnostic tests respond to the same blockage level — and why stress tests and calcium scores create a dangerous false sense of security.
Lipid levels in patients hospitalized with coronary artery disease
Analysis of 136,905 hospitalizations showed ~50% of heart attack patients had LDL <100 mg/dL ("normal"). Only 1.4% had ideal lipid profiles.
Statin Eligibility Among First MI Patients Under 65
45-61% of first MI patients under 65 would not have qualified for statin therapy under current guidelines, exposing massive gaps in risk stratification.
Mechanisms of Plaque Rupture
75% of acute coronary events result from rupture of non-obstructive, lipid-rich vulnerable plaques that cause only 20-40% stenosis — invisible to stress testing.
Diagnostic Accuracy of Exercise Stress Testing: A Meta-Analysis
Exercise stress testing has a sensitivity of only 60-70% for detecting obstructive CAD, with significant false-negative rates in single-vessel disease.
Ischemia and No Obstructive Coronary Artery Disease (INOCA)
~70% of patients presenting with MI show no ischemia on prior stress testing, underscoring the limitations of functional testing for risk prediction.
Passes the test. Stress tests only detect significant flow limitations (typically 70% or greater narrowing). They miss early-stage, non-obstructive plaques that cause most heart attacks.
Shows no calcified plaque. However, calcium scores are completely blind to soft, non-calcified lipid plaques that are highly prone to rupture.
Visualizes and quantifies both calcified and soft plaque volumes, allowing for precise risk stratification and targeted lifestyle or medical optimization.
A Coronary CT Angiogram (CCTA) with AI analysis — like the Cleerly platform — is a 256-slice HD CT scan that directly visualizes your coronary arteries. Unlike a calcium score (which only sees calcified plaque) or a stress test (which only detects severe blockages), a CCTA sees all plaque types — including the soft, unstable plaques that cause most heart attacks.[18]
Cleerly's AI analysis quantifies total plaque volume, categorizes plaque type (calcified, mixed, non-calcified), and tracks changes over time — enabling precise measurement of whether your interventions are working. Cleerly has received FDA 510(k) clearance, making it the gold standard in AI-enhanced cardiac imaging.
The CAPIRE study demonstrated that noncalcified plaque volume is superior to stenosis severity for predicting cardiovascular events. Dr. Robert Hurst notes he's seen patients with clean CT angiograms but significant plaque in the carotids — and vice versa. A thorough evaluation assesses both coronary and carotid vasculature to capture the full picture. This is the difference between guessing and knowing.
SCOT-HEART: Coronary CT Angiography and 5-Year Risk of Myocardial Infarction
CCTA-guided management led to a 41% reduction in coronary heart disease death and nonfatal MI at 5 years compared to standard care.
CAPIRE: Coronary Atherosclerosis Progression and Its Role in Clinical Events
Noncalcified plaque volume on CCTA was superior to stenosis severity for predicting future cardiovascular events, supporting volumetric plaque analysis.
AI-Enabled Quantitative CT Angiography for Coronary Artery Disease (Cleerly)
Cleerly's AI-based quantitative analysis of CCTA demonstrated high accuracy in plaque characterization and volume quantification, earning FDA 510(k) clearance.
PROMISE Trial: Outcomes of Anatomical vs Functional Testing for CAD
CCTA detected significantly more coronary artery disease than functional stress testing, with ~70% of MI patients showing no ischemia on prior stress tests.
Comparison of Novel Risk Markers for Improvement in CV Risk Assessment
Coronary artery calcium and CT-based imaging outperformed other novel markers for risk reclassification in intermediate-risk individuals.
1958-1964: For decades, you've been told to avoid fat to protect your heart. That advice came from Ancel Keys' Seven Countries Study — a landmark study that cherry-picked data from 7 of 22 available countries, selecting only those that supported its conclusion while ignoring those that didn't.[1, 2]
1968-1973: The Minnesota Coronary Experiment — a major clinical trial — found that following the "low-fat" advice actually increased deaths: a 22% increased risk of death for every 30 mg/dL drop in cholesterol. The results were so inconvenient they were buried for decades. You were never told about this.[3]
1966-1973: The Sydney Diet Heart Study reached similar conclusions — replacing saturated fat with vegetable oils increased mortality. Those results were buried until 2013, when researchers recovered and re-analyzed the original data.[4]
The Female Paradox: Women have 300% fewer heart attacks than men despite having consistently higher total cholesterol levels throughout life. If cholesterol were the primary driver, this pattern would be impossible to explain.
1990s: Scientists discovered that chronic inflammation — not dietary fat — is what actually damages your arteries.[6]
2000s: Research confirmed that the number of atherogenic particles (ApoB) is a superior predictor of heart attacks compared to cholesterol content (LDL-C).[12, 25]
The Lipid–Heart Hypothesis and the Keys Equation
Systematic critique of Ancel Keys' diet-heart hypothesis, showing data selection bias in the Seven Countries Study and failure of the hypothesis in subsequent trials.
Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73)
Recovered data showed replacing saturated fat with vegetable oil lowered cholesterol but increased mortality — a 22% increased risk of death per 30 mg/dL cholesterol reduction.
Use of dietary linoleic acid for secondary prevention of coronary heart disease and death (Sydney Diet Heart Study)
Re-analysis of buried data from the Sydney Diet Heart Study found increased rates of death from all causes and coronary heart disease when saturated fat was replaced with omega-6 linoleic acid.
Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations (JACC State-of-the-Art Review)
Concluded that the recommendation to limit saturated fat intake has persisted despite mounting evidence to the contrary. Whole-food sources of SFA are not associated with CVD risk.
Lab reference ranges define "normal" as approximately the 2.5th to 97.5th percentile of the general population. But only 12.2% of American adults are metabolically healthy. That means "normal" is defined by a population where ~88% already have at least one marker of metabolic dysfunction.
Fasting Insulin Example: The standard "normal" range is 2.6–24.9 µIU/mL. Functional medicine considers the optimal range to be below 8 µIU/mL — anything above signals developing insulin resistance. Your doctor may tell you "your labs look fine" while insulin resistance silently progresses for years.
The Framingham Correction: Data from the Framingham Heart Study shows that LDL cholesterol is not a significant risk factor unless above 300 mg/dL — once you correct for HDL and triglycerides. The standard cholesterol panic often misses the real metabolic picture.
In the functional medicine community, functional medicine practitioners identify and address subclinical disease by using lab reference ranges geared towards optimization instead of just "normal." The gap between "normal" and "optimal" is where most cardiovascular disease develops silently — and where most prevention opportunities are missed.
Prevalence of Optimal Metabolic Health in American Adults
Only 12.2% of American adults meet criteria for optimal metabolic health. 88% have at least one marker of metabolic dysfunction.
Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program
For every 1 mg/dL per year drop in serum cholesterol, there was a 14% increase in cardiovascular mortality and an 11% increase in overall mortality.
LDL Particle Number and Risk of Future CVD in the Framingham Offspring Study
LDL particle number (LDL-P) is a better predictor of cardiovascular events than LDL cholesterol content (LDL-C). When discordant, LDL-P determines risk.
Insulin Resistance and Coronary Heart Disease in Nondiabetic Individuals
Insulin resistance is an independent cardiovascular risk factor even in non-diabetic individuals, driving atherogenesis through multiple pathways beyond glucose control.
Unless you're one of the small percentage of people who have familial hypercholesterolemia (FH), there is a root cause behind your elevated cholesterol — and it's something you can address. Medication can be a piece of the puzzle, but suppressing cholesterol numbers alone provides a false sense of security for both patients and healthcare providers.
"Moral Licensing": Behavioral psychology calls this phenomenon moral licensing — the unconscious belief that because you've done one "good" thing (taking a pill), you've earned the right to relax elsewhere. The medication gives false reassurance to the patient. Lower lipid levels give false reassurance to the doctor. The conditions that created the problem — the metabolic dysfunction, the inflammation, the insulin resistance — continue unchecked.
Reduces LDL by 5-10% at most. This is the conventional advice patients receive — and the ceiling is low.
Reduces triglycerides by 20-30%, improves insulin sensitivity, lowers small dense LDL particles — addressing root causes.
Taking a statin or other cholesterol medication does not by itself significantly reduce risk if the entire terrain that created the high cholesterol still exists. It is incumbent upon you to do the work — change the lifestyle, find the source of your inflammation, take leadership over your health. The comfort of medication can distract from that work. And medications themselves carry risks — iatrogenesis (side effects from medications and medical procedures) is itself a cardiovascular risk factor that often goes unacknowledged.
You are the CEO of your health. We provide data, education, analysis, and guidance — but lasting transformation happens when you take ownership of your health journey. Don't let your health be limited by your healthcare.
Different time trends of caloric and fat intake between statin users and nonusers among US adults
Statin users increased calorie intake by 9.6% and fat intake by 14.4% over a decade, while non-users showed no significant changes — demonstrating the "moral licensing" effect of medication.
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Insulin resistance drives atherosclerosis through multiple metabolic pathways that are not addressed by cholesterol-lowering medications alone.
Effects of dietary carbohydrate restriction on lipids and lipoproteins: a meta-analysis
Reducing carbohydrate intake lowered triglycerides by 20-30% and increased HDL cholesterol, with more favorable changes than low-fat dietary interventions.
Inflammation in atherosclerosis: from pathophysiology to practice
Chronic inflammation — not cholesterol levels alone — drives the atherosclerotic process, from initiation through plaque rupture and clinical events.
Statins remain the default first-line treatment in conventional cardiology. They do lower LDL-C and have documented pleiotropic benefits (anti-inflammatory, endothelial stabilization).[20] But the conversation around statins is often incomplete — both from proponents who present them as sufficient, and from detractors who dismiss them entirely.
The Diabetes Risk: A meta-analysis by Sattar et al. of 91,140 participants across 13 statin trials found a 9% increased risk of developing diabetes. This risk is dose-dependent — higher-intensity statin therapy carries greater risk.
Follow the Money: When the LDL cholesterol guidelines were last revised, 8 of the 9 panel members had financial ties to statin manufacturers. Pfizer made $125 billion from Lipitor alone — making it the best-selling drug in pharmaceutical history. This doesn't invalidate the science, but it demands scrutiny.
Many patients feel unable to ask critical questions about medications they're being prescribed. We believe you deserve a nuanced, honest conversation about the benefits, limitations, and side effects of any medication. Statins may be appropriate for you — but they should never be the entire plan.
Statins for Heart Disease Prevention (Without Prior Heart Disease)
NNT of ~104 over 5 years for primary prevention. 1 in 104 avoids a heart attack; none avoid death. 1 in 50 develop diabetes; 1 in 10 experience muscle damage.
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Meta-analysis of 91,140 participants across 13 trials found a 9% increased risk of incident diabetes with statin therapy. Risk increased with higher-dose regimens.
Pleiotropic effects of statins
Statins have anti-inflammatory and endothelial-stabilizing benefits beyond LDL lowering, which may account for much of their clinical benefit.
Cholesterol and all-cause mortality in the oldest old: the Leiden 85-plus Study
In elderly populations, higher cholesterol was associated with lower mortality, challenging the universal applicability of cholesterol-lowering interventions.
Lipid paradox in longevity: high LDL associated with lower mortality in Sardinian Blue Zone centenarians
In Sardinian adults aged 90+, LDL ≥ 130 mg/dL was associated with 40% lower risk of death — the "cholesterol paradox" of extreme longevity.
Every year, over 600,000 stent procedures are performed in the United States. Patients leave the hospital believing they've been "fixed" — that the blockage has been opened and the danger has passed. But landmark clinical trials tell a very different story: for patients with stable coronary artery disease, stents do not reduce the risk of future heart attacks or death compared to optimal medical therapy alone.[26]
What stents actually do: Stents are designed to treat significant stenoses (≥70% narrowing) that cause symptoms — chest pain (angina), shortness of breath on exertion, or documented ischemia on stress testing. They mechanically prop open a narrowed artery, restoring blood flow to the downstream heart muscle. For acute heart attacks (ST-elevation myocardial infarction), emergency stenting is life-saving and unquestioned. The problem arises when stenting is applied to stable disease — blockages found on routine testing in patients without acute symptoms.
Why stents don't prevent heart attacks: The fundamental misconception is that the biggest blockage is the most dangerous. In reality, most heart attacks originate from plaques that are only 20–40% stenotic — too small to show up on a stress test, too small to cause symptoms, but biologically volatile. These vulnerable plaques have a large lipid-rich core, a thin fibrous cap, and active inflammation that makes them prone to sudden rupture.[27] When they rupture, they trigger an acute blood clot (thrombosis) that completely occludes the artery within minutes. A stent placed in a different, more narrowed artery does nothing to address this risk.
The body's built-in bypass: For slowly progressive blockages, your body has a remarkable adaptation — collateral blood vessels (natural bypass channels) that form around the obstruction over time. These collateral networks can supply enough blood to the heart muscle that even a severely narrowed artery may not cause ischemia at rest or during moderate activity. This is why many patients with 70–80% blockages are asymptomatic — their collateral circulation has compensated.
The COURAGE trial (2,287 patients) demonstrated the same finding years earlier: adding stenting to optimal medical therapy did not reduce death, heart attack, or other major cardiovascular events in stable coronary disease. The ORBITA trial went further — in a sham-controlled, double-blind design, stenting did not improve exercise capacity more than a placebo procedure in patients with single-vessel stable angina.[28]
The degree of narrowing isn't what usually causes a heart attack — it's plaque composition, inflammation, oxidative stress, and endothelial dysfunction. You can have a perfectly successful stent procedure and still have a heart attack weeks later from a completely different vulnerable plaque that no one treated — because it wasn't visible as a "significant" blockage on the angiogram.
The message is clear: stents are an important tool for symptom relief and acute emergencies. But they are not a preventive strategy. True prevention means addressing the systemic drivers of plaque vulnerability — inflammation, insulin resistance, oxidative stress, endothelial dysfunction — not just the largest visible blockage. If you've been told you need a stent for stable disease, you deserve to know about this evidence before making that decision.
Initial Invasive or Conservative Strategy for Stable Coronary Disease (ISCHEMIA Trial)
Among 5,179 patients with stable coronary disease and moderate-to-severe ischemia, an initial invasive strategy (stenting or bypass) did not reduce the risk of ischemic cardiovascular events or death compared to optimal medical therapy over 3.2 years of follow-up.
Optimal Medical Therapy with or without PCI for Stable Coronary Disease (COURAGE Trial)
In 2,287 patients with stable angina, PCI added to optimal medical therapy did not reduce death, MI, or other major cardiovascular events compared with optimal medical therapy alone over 4.6 years.
Percutaneous Coronary Intervention in Stable Angina (ORBITA Trial)
In this sham-controlled, double-blind randomized trial, PCI did not improve exercise time more than a placebo procedure in patients with single-vessel stable angina — challenging the assumption that stenting provides symptomatic benefit beyond a placebo effect.
Thin-Cap Fibroatheroma as a High-Risk Plaque Feature
Pathological studies demonstrated that most fatal heart attacks arise from rupture of thin-cap fibroatheromas — plaques with large lipid cores and fibrous caps <65 microns — rather than from the most severely stenotic lesions.
Collateral Circulation in Coronary Artery Disease
Well-developed coronary collateral circulation provides a natural bypass that protects against myocardial ischemia and infarction, and is associated with reduced mortality independent of the severity of coronary stenosis.
We can critique the current system without criticizing the people within it. Everyone is doing the best they can with the information and training they have. But the economic incentive structure is clear — and it doesn't favor prevention.
The INTERHEART Study: A landmark global case-control study of 29,972 participants across 52 countries found that 9 modifiable risk factors account for over 90% of the risk of a first heart attack — including smoking, lipids, hypertension, diabetes, obesity, diet, physical activity, alcohol, and psychosocial factors. Almost all heart attacks are preventable.
The ISCHEMIA Trial: This landmark 2020 trial of 5,179 patients with stable coronary artery disease found that optimal medical therapy produced outcomes equal to invasive procedures (stents and bypass). For stable patients, aggressive lifestyle and medication management is just as effective as surgery — at a fraction of the cost and risk.
Randomized controlled trials are valuable, but they are also expensive, rigid, and heavily influenced by funding sources. The result is a medical literature dominated by what can be studied profitably — namely, pharmaceuticals — while broader, potentially more powerful interventions (like diet, sleep, and community) go underexamined.
3 Billion Beats changes this dynamic by prioritizing early detection, root-cause education, and continuous coaching before a crisis occurs.
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART)
Nine modifiable risk factors account for over 90% of the population attributable risk of a first myocardial infarction across all ages, sexes, and regions worldwide.
Initial Invasive or Conservative Strategy for Stable Coronary Disease (ISCHEMIA Trial)
Among patients with stable coronary disease and moderate-to-severe ischemia, an initial invasive strategy did not reduce clinical events compared to optimal medical therapy alone.
Heart Disease and Stroke Statistics — 2024 Update
US CVD spending exceeds $400 billion annually, projected to reach $1.8–1.9 trillion by 2050. CVD remains the leading cause of death globally.
Effectiveness of Lifestyle Modification for Prevention of Cardiovascular Disease
Up to 80% of cardiovascular events are preventable through modifiable lifestyle factors including diet, exercise, smoking cessation, and weight management.
"A doctor who spends half an hour teaching a patient how to avoid a heart attack might earn $95. But the system makes $15,000 for a heart cath and $240,000 for a bypass. What do you think gets rewarded?"
Randomized controlled trials are valuable, but they are also expensive, rigid, and heavily influenced by funding sources. The result is a medical literature dominated by what can be studied profitably — namely, pharmaceuticals — while broader, potentially more powerful interventions (like diet, sleep, and community) go underexamined.
3 Billion Beats changes this dynamic by prioritizing early detection, root-cause education, and continuous coaching before a crisis occurs.
The most important message in cardiovascular medicine: heart disease is not a one-way street. Landmark clinical trials have demonstrated that intensive, root-cause interventions can halt progression and even lead to regression of existing atherosclerosis.
Esselstyn's Plant-Based Trial: Dr. Caldwell Esselstyn's long-term follow-up showed a 0.6% cardiac event rate among adherent patients vs. 62% event rate among non-adherent patients. Adherence to intensive lifestyle change was the determining factor.
Mount Abu Open Heart Trial: This groundbreaking Indian study demonstrated an 18% decrease in coronary artery narrowing and a 4-fold decrease in myocardial infarction by 6 years. Remarkably, the single biggest contributing factor was raja yoga meditation — not diet or exercise, though both were included.
These trials converge on a consistent message: when patients commit to comprehensive lifestyle change — addressing diet, movement, stress, sleep, and emotional health together — the body has a remarkable capacity for self-repair.
Intensive lifestyle changes for reversal of coronary heart disease
82% of the lifestyle-intervention group showed measurable regression of coronary atherosclerosis at 1 year, using diet, exercise, stress management, and group support — without lipid-lowering drugs.
A way to reverse CAD? (Esselstyn plant-based outcomes)
Among 198 patients with established CAD, adherent plant-based diet patients had a 0.6% cardiac event rate vs. 62% among non-adherent patients over 3.7 years of follow-up.
Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after MI (Lyon Diet Heart Study)
Mediterranean-style diet achieved 50-70% reduction in recurrent cardiovascular events despite similar cholesterol levels between groups — highlighting non-lipid pathways of protection.
Mount Abu Open Heart Trial: role of meditation in regression of coronary atherosclerosis
Demonstrated 18% decrease in coronary narrowing and 4-fold reduction in MI by 6 years. Raja yoga meditation was identified as the single most important contributing factor.
ApoB vs LDL-C as markers of cardiovascular risk (meta-analysis)
Analysis of 233,455 subjects confirmed ApoB as the most potent lipid marker of cardiovascular risk. When ApoB and LDL-C are discordant, ApoB is the accurate predictor.
Conventional cardiology excels at acute care — managing heart attacks, placing stents, performing bypass surgery. But it was not designed for the kind of deep, personalized, upstream prevention that most heart disease actually requires.
The 4P Model: Functional cardiology is built on four principles:
Advanced biomarkers and imaging to detect disease 10-20 years before symptoms appear.
Root-cause interventions that stop disease progression — not just managing symptoms after the fact.
Every plan is built around your unique biology, genetics, lifestyle, and metabolic profile.
You are an active partner in your care — not a passive recipient of prescriptions.
Functional cardiology asks different questions: Why is your cholesterol elevated? What is driving your inflammation? Where is the metabolic dysfunction originating? The real question is: why is the endothelium injured? Instead of reaching for a prescription pad first, the functional approach investigates root causes using advanced diagnostics — then supports a personalized plan that addresses the full picture.
The future of healthcare is participatory. We provide data, education, analysis, and guidance — but ultimately, lasting transformation happens when you are empowered to take ownership of your health journey. You are the CEO of your health.
Vascular Endothelial Glycocalyx as a Mechanism of Vascular Endothelial Dysfunction and Atherosclerosis
Endothelial glycocalyx damage is an early initiating event in atherosclerosis — supporting the functional cardiology emphasis on endothelial health over cholesterol levels.
Inflammation and atherosclerosis: from pathophysiology to practice
Inflammation — not cholesterol alone — drives atherosclerosis from initiation through plaque rupture. This supports the multi-factor, root-cause approach of functional cardiology.
Predictive, preventive, personalized and participatory medicine (4P medicine)
The 4P medicine model represents a paradigm shift from reactive disease treatment to proactive wellness optimization through systems biology and individualized care.
Oxidized LDL as a biomarker of cardiovascular diseases
Oxidized LDL — not native LDL — is the atherogenic species. This distinction underscores why simple LDL-C measurement misses much of the cardiovascular risk picture.
Your Heart Health Score is a 0-100 score built from three pillars that capture the full spectrum of cardiovascular risk — not just cholesterol. It's powered by your labs, imaging, wearables, and health history, and it tracks how your health improves over time.
Insulin sensitivity, energy processing, metabolic efficiency. How well your body manages fuel.
Cardiovascular stress tolerance, recovery capacity, heart rate variability. How well your system adapts.
Systemic inflammatory burden — acts as a capacity multiplier. Higher inflammation = lower ceiling on the other pillars.
Heart Rate Variability (HRV): One of the most important resilience markers tracked by wearables. Research shows that low HRV is associated with a 32-45% increased risk of a first cardiovascular event. HRV reflects autonomic nervous system balance — your body's ability to adapt to stress, recover from exertion, and maintain cardiovascular homeostasis.
Life's Essential 8: Updating and Enhancing the AHA's Construct of Cardiovascular Health
Updated AHA framework with 8 key components of CV health (diet, activity, nicotine, sleep, weight, blood lipids, blood glucose, blood pressure). Only ~20% of US adults achieve ideal levels.
Heart rate variability as a predictor of cardiovascular events: the ARIC study
Low HRV was associated with 32-45% increased risk of a first cardiovascular event, independent of traditional risk factors. HRV reflects autonomic function and cardiac resilience.
Prevalence of Optimal Metabolic Health in American Adults
Only 12.2% of American adults are metabolically healthy by comprehensive criteria — demonstrating the gap between standard "normal" and true optimal health.
Inflammation and atherosclerosis: role of C-reactive protein in risk assessment
Inflammatory markers like hs-CRP independently predict cardiovascular events and improve risk stratification beyond lipid levels alone — supporting multi-pillar scoring approaches.
GAIN — Go All In — is a 16-week coaching and transformation program created by Betsy Shor through the Health is Wealth Institute. It is the behavioral and coaching foundation of the Journey experience inside the 3 Billion Beats app. The program integrates functional medicine, nutrition science, cognitive behavioral therapy (CBT), and behavior change psychology into five progressive phases.
Even the most well-intentioned practitioner can't do this for you in a 10-minute appointment twice a year. GAIN puts the tools and framework directly in your hands — coaching, community, and clinical guidance combined. Because even if you know what to do, many people struggle to do what they know. GAIN bridges that gap.
You are the CEO of your health. We provide data, education, analysis, and guidance — but ultimately, lasting transformation happens when you are empowered to take ownership of your health journey. Because every heartbeat matters. And across a lifetime, we each receive roughly 3 billion of them.
Implementation intentions and goal achievement: A meta-analysis of effects and processes
Meta-analysis confirmed that implementation intentions ("if-then" plans) increase goal attainment by 2-3x compared to goal intentions alone across health behavior domains.
Does changing behavioral intentions engender behavior change? A meta-analysis of the experimental evidence
Intentions account for only 28% of variance in behavior. Bridging the "intention-behavior gap" requires structured implementation strategies — the core principle behind GAIN.
Cognitive behavioral therapy for health behavior change
CBT-based interventions effectively improve health behaviors including diet, exercise, and stress management — with lasting effects when combined with ongoing coaching support.
Behavioral counseling interventions to promote a healthy diet and physical activity for CVD prevention
Behavioral counseling interventions for adults with CVD risk factors produce clinically meaningful improvements in diet, physical activity, and cardiovascular outcomes.
Corwin isn't a chatbot. He's a cognitive AI health companion built on a neuroscience-inspired architecture with five distinct memory systems — modeled after human cognition. He remembers every conversation, every lab result, every goal. He gets smarter about you over time.
Corwin's core intelligence runs entirely on Google's Gemini model family. His primary reasoning engine is Gemini 3.5 Flash — used for chat, voice consultations, intake conversations, health story generation, and food analysis. For latency-critical moments like greetings and memory extraction, Gemini 3.1 Flash-Lite delivers sub-second responses. His voice — the Enceladus voice via Gemini Live API — generates native audio through a WebSocket pipeline, not traditional text-to-speech. The result is natural, expressive conversation that feels human.
Corwin's immediate context window — what he's actively thinking about during your conversation. An AAAK Budget Packer with a 5-tier priority system protects critical safety information (allergies, medications, clinical ground truth) even under context pressure. In voice mode, a strict 12K-character budget ensures natural conversational rhythm; in text mode, a 48K budget allows deeper analytical responses. An Affective Override drops to a minimal 2K budget in crisis situations, focusing entirely on safety.
Exact conversational transcripts and temporal events — the raw historical fabric. A Chrono-Semantic Engine with a Two-Stage Lexical Router bypasses vector search for time-based queries ("What did my labs show in March?") — using NLP date parsing first, then BM25 IDF scoring via SQLite FTS5. Emotional context is tracked across sessions as its own memory category with a 2-year decay curve. Critical diagnoses receive Clinical Gravity Wells — making them immune to temporal decay.
Corwin's foundational medical education: 1,188 embedded clinical knowledge chunks in a 768-dimensional vector space, covering functional cardiology, metabolic health, and lifestyle medicine. A Sentra Consolidator uses geometric compression to organize canonical facts. A weekly quality audit (the "Sunday Linter") detects contradictions and quarantines bad data. Cross-event synthesis (§XSYNTH) discovers emergent patterns across your health history that neither you nor any single conversation would surface alone.
Tracks your health trajectory to anticipate future patterns. A Gemini 3.1 Flash-Lite vitals forecaster predicts the next 24 hours of biometric telemetry from your wearables. Proactive outreach alerts trigger when predicted vitals drop >25% from baseline. The system suppresses expected data via a Surprise-Based Novelty Gate and learns from prediction errors — only writing facts that violate its internal model of your health. This saves ~40% of context tokens through expectation-based compression.
Corwin can write and execute his own programmatic workflows in a sandboxed environment. An air-gapped QuickJS WASM runtime with <10ms startup, 64MB memory cap, and 5-second timeout allows safe code execution. An AST Static Safety Validator screens every script before execution. High-risk actions require human-in-the-loop approval (HITL Risk Tiering). Automated self-correction captures runtime exceptions and regenerates scripts up to 3 times — learning from each failure.
corwin-right-brain-v4-abstention) deployed to a Vertex AI endpoint — generates structural reasoning drafts (§GLOBAL_DRAFT). A "Left Brain" (Gemini 3.5 Flash) applies clinical safety and epistemic rigor. In testing, Gemini independently detected and vetoed an incorrect causal chain from the Right Brain — an emergent safety behavior we call the "Epistemic Veto."
For complex clinical reasoning, Corwin convenes a multi-AI-lab Diagnostician Council (v3.2) — a deliberative system that synthesizes perspectives from four independent agents across four different AI providers:
DeepSeek R1 — Chain-of-thought reasoning specialist. Identifies hidden connections and non-obvious differential diagnoses through deep sequential analysis.
Qwen 3 (235B) — Independent mechanistic perspective. Analyzes physiological pathways and metabolic interactions from a different model architecture to reduce confirmation bias.
Claude Opus 4 — High-precision medical reasoning. Provides careful, evidence-weighted analysis with strong calibration on uncertainty.
Gemini 3.5 Flash — Consensus builder. Runs two rounds of deliberation, resolves disagreements, and produces a unified clinical assessment with confidence-weighted recommendations.
Corwin doesn't use the same cognitive intensity for every interaction. A Dynamic Thinking Router matches reasoning depth to the task at hand — from MINIMAL (greetings, small talk) through LOW and MEDIUM, up to HIGH for complex clinical analysis. This ensures fast, natural responses for simple exchanges while reserving full analytical power for moments that matter.
Geometry of Consolidation: Dual-Process Memory Architecture
Proposes geometric compression of canonical facts for memory consolidation — the theoretical foundation for Corwin's dual-process memory system and semantic knowledge organization.
Predictive Coding and Predictive Routing
Theoretical backbone of Corwin's entire memory system. Predictive coding enables the system to suppress expected data and learn from prediction errors.
HLA: Hierarchical Long-term Associative Memory
Inspired Clinical Gravity Wells and CMS oscillatory cycles (Gamma/Alpha/Delta) that govern memory consolidation timing and priority in Corwin's architecture.
Lost in the Middle: How Language Models Use Long Contexts
Demonstrated that LLMs attend most to the beginning and end of context windows. Informed Corwin's end-loading strategy for episodic recall injection.
Effectiveness of AI-Based Interventions for Cardiovascular Risk Factor Management
AI coaching improves treatment adherence by 20-30%. Hybrid AI + human clinician models achieve highest effectiveness — validating Corwin's design as a complement to clinical care.
Corwin's architecture is informed by peer-reviewed research in computational neuroscience and machine learning:
Corwin's full five-memory architecture — including Working Memory, Episodic Memory, Semantic Memory, Predictive Memory, and Procedural Memory — is detailed in the Overview tab above.
sarah_runs My dad had a "normal" stress test 6 months before his heart attack 😳 #3BBDeepDives #DiagnosticBlindspots
dr.mike.wellness This is why I order CAC scores. Standard testing misses subclinical disease. #3BBDeepDives #DiagnosticBlindspots